Evidence concerning the safety of rosiglitazone continues to evolve
In February 2010, the United States Senate Committee on Finance released a report on the safety of rosiglitazone.1 The report concluded that there were possible cardiac risks associated with rosiglitazone and that the manufacturer, GlaxoSmithKline (GSK), was aware of this well before it became public. The authors further stated that, rather than warn patients and regulatory authorities promptly, GSK executives chose to intimidate independent physicians who publicised the possible risks, minimise the impact of adverse findings, and downplay the possibly beneficial cardiovascular effects of the other available drug in the class, pioglitazone.1
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
Timothy Davis has served on advisory boards for Eli Lilly (which markets pioglitazone in Australia) and GSK, has had the costs of attendance at national and international scientific meetings covered by both companies, and has received lecture fees from GSK. Johannes Prins has served on advisory boards for GSK, and has had the costs of attendance at national and international scientific meetings covered and received lecture fees from both GSK and Eli Lilly.